Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample

L B VanWagner1,2, M Serper3, R Kang4

  • 1Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

Insights

Major adverse cardiovascular events (MACE) affect 11% of liver transplant recipients, impacting survival. Pre-transplant atrial fibrillation and stroke significantly increase MACE risk, identifying high-risk candidates.

Area of Science:

  • Cardiology
  • Hepatology
  • Transplantation Medicine

Background:

  • Major adverse cardiovascular events (MACE) assessment post-liver transplantation (LT) lacks multicenter data.
  • Understanding MACE risk factors is crucial for improving LT outcomes.

Purpose of the Study:

  • To assess factors associated with 30- and 90-day MACE after LT.
  • To evaluate the impact of MACE on 1-year survival post-LT.

Main Methods:

  • Analysis of an integrated database from University HealthSystem Consortium and Organ Procurement and Transplant Network (February 2002–December 2012).
  • Multivariate Poisson regression used to identify MACE predictors.
  • MACE defined as myocardial infarction, heart failure, atrial fibrillation, cardiac arrest, pulmonary embolism, and/or stroke.

Main Results:

  • MACE occurred in 8% (30-day) and 11% (90-day) of 32,810 LT recipients.
  • Independent MACE predictors included age >65, alcoholic cirrhosis, NASH, elevated creatinine, baseline AF, and stroke.
  • MACE was linked to significantly lower 1-year survival (79% vs. 88%).

Conclusions:

  • MACE impacts 11% of LT recipients and negatively affects survival.
  • Pre-LT atrial fibrillation and stroke are substantial MACE risk factors.
  • Identifies high-risk LT candidates for closer cardiovascular monitoring.

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
681
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
148
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
747